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Abstract 
Background: Several antidiabetic drugs (i.e., sulfonylureas; SU, rosiglitazone) have been reported to be associated 
with increased risks of cardiovascular diseases (CVD) in patients with type 2 diabetes mellitus (T2DM). Dipeptidyl 
peptidase‑4 inhibitors (DPP4i) are newly available antidiabetic drugs. Most studies only compared DPP4i with a 
placebo or SU, or targeted a specific CVD event of interest (i.e., heart failure; HF). Comparative research of CVD risks of 
DPP4i with other antidiabetic drugs (i.e., metformin, thiazolidinediones, meglitinides, acarbose, and insulin) remains 
scarce. This study was aimed to assess comparative risks of CVD, including ischemic stroke, myocardial infarction (MI) 
and HF, and hypoglycemia of DPP4i with other antidiabetic drugs.
Methods: We utilized Taiwan’s National Health Insurance Research Database. A total of 123,050 T2DM patients newly 
prescribed oral antidiabetic treatments were identified in 2009–2010 and followed until 2013. Outcome endpoints 
included a composite of CVD events: hospitalizations for ischemic stroke, MI and HF, and hypoglycemia. Time‑varying 
Cox proportional hazards regression was applied to assess the time to event hazards of various antidiabetic drugs, 
adjusted for patients’ demographics, comorbidity, diabetic complications, and co‑medications. Additional analyses 
were performed for the patients with and without CVD history, respectively.
Results: DPP4i users had significantly lower CVD risks as compared to that of non‑DPP4i users (adjusted hazard ratio 
[aHR]: 0.83, 95 % confidence interval [CI]: 0.76–0.91). Compared to DPP4i users, meglitinides (aHR 1.3, 95 % CI 1.20–
1.43) and insulin users (aHR 3.73, 95 % CI 3.35, 4.14) had significantly higher risks for composite CVD, as well as those 
for stroke, MI, HF, and hypoglycemia. Additionally, metformin users had significantly lower risks for composite CVD 
risk (aHR 0.87, 95 % CI 0.79–0.94), as well as those for MI, HF, and hypoglycemia, as compared to those of DPP4i users. 
Although there was a trend toward low CVD risks in pioglitazone users, the role of potential confounding by indica‑
tion cannot be excluded.
Conclusions: DPP4i‑treated T2DM patients had lower risks for CVD as compared to those for non‑DPP4i users, except 
metformin users.
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Background
Cardiovascular diseases (CVD) are highly prevalent 
complications in patients with type 2 diabetes mellitus 
(T2DM), which are the leading of deaths in such indi-
viduals [1]. However, with emerging trials evaluating car-
diovascular effects of antidiabetic drugs, not all the drugs 
appear to reduce CVD risks in T2DM patients. Sulfo-
nylureas (SU) have been reported to be associated with 
increased CVD risks [2, 3]. The meta-analyses of clinical 
trials [4] and observational studies [5] showed that rosigl-
itazone was associated with excess myocardial infarction 
(MI) and heart failure (HF) risks, although a recent large 
prospective trial, the RECORD, did not have sufficient 
data to determine if it yields a higher risk for MI as com-
pared to metformin or SU [6]. Conversely, the cardiovas-
cular benefits have been seen with several antidiabetic 
drugs: metformin for T2DM patients with overweight 
[7], acarbose for the patients with impaired glucose toler-
ance (IGT) [8, 9], and empagliflozin in those at high risk 
of CVD events [10].
Dipeptidyl peptidase-4 inhibitors (DPP4i) are newly 
available oral hypoglycemic agents (OHAs). DPP4i sup-
presses the breakdown of incretin hormones glucagon-
like peptide-1 and glucose-dependent insulinotropic 
peptide, achieving glycemic control. The CVD risks 
associated with DPP4i treatment have been investi-
gated. DPP4i was shown to not have increased risks for 
ischemic stroke and MI [11–19]. Recent trials noticed 
that saxagliptin (SAVOR-TIMI 53 trial [12]) and aloglip-
tin (EXAMINE [13]) had a higher risk for heart failure 
(HF) as compared to placebo, while a large observational 
study of 127,555 T2DM patients in Italy showed a sig-
nificantly lower HF risk of DPP4i as compared with SU 
[20]. However, most studies only compared DPP4i with 
a placebo [12, 13] or SU [11, 15, 17, 18, 21], or targeted 
a specific CVD event of interest (i.e., HF [20]). Research 
that assesses comparative CVD risks of DPP4i with other 
antidiabetic drugs (i.e., metformin, thiazolidinediones 
(TZDs), meglitinides, acarbose, and insulin) remains 
scarce.
The present study utilizes a comprehensive national 
cohort of diabetic patients in Taiwan to evaluate the risks 
of CVD, including stroke, MI and HF, and hypoglycemia 
associated with DPP4i as compared with those of other 
antidiabetic drugs.
Methods
The Institutional Review Board of National Cheng Kung 
University Hospital approved the study before com-
mencement (A-ER-103-298).
Data source
We used the Longitudinal Cohort of Diabetes Patients 
database (LHDB) 1996–2013, retrieved from the National 
Health Insurance Research Database (NHIRD), provided 
by Taiwan’s National Health Research Institutes. Taiwan’s 
NHIRD is population-based and derived from the claims 
data from the National Health Insurance program, a 
mandatory-enrollment, single-payment system that cov-
ers over 99 % of Taiwan’s population. The LHDB consists 
of a random sample of 120,000 de-identified diabetes 
incident cases from 1996 to 2013, who were tracked back 
to 1996 and followed up to 2013 to establish a longitudi-
nal cohort. The LHDB is most representative of Taiwan’s 
diabetic population and provides the opportunity to con-
duct longitudinal studies to evaluate long-term outcomes 
of diabetes treatments.
Study cohort
We identified patients aged ≥20  years with T2DM 
diagnosis (International Classification of Dis-
eases, Ninth Revision, Clinical Modification, ICD-
9-CM  =  250.0X–250.9X, X  =  0 or 2) from 1999–2013 
LHDB. We further selected cases with any antidiabetic 
drug exposure during 2009–2010. The first claim date 
of an antidiabetic drug prescribed in 2009–2010 was 
defined as the index date. Patients who had any anti-
diabetic drugs before the index date were excluded, in 
order to include new users of antidiabetic drugs. The 
observation for each case started from the index date to 
the date of death or the end of 2013. The maximum fol-
low-up time was 5 years (2009–2013) and the minimum 
was 3 years (2011–2013). The primary outcome of inter-
est was major adverse cardiovascular events (MACEs) 
(a composite of CVD events including hospitalizations 
for ischemic stroke [ICD-9 codes 430–438], MI [ICD-9 
codes 410, 412], and HF [ICD-9 codes 428]) and indi-
vidual components of CVD. The secondary outcome was 
a hospitalization for hypoglycemia (ICD-9 codes: 250.8, 
251.0, 251.1, and 251.2).
Exposure to antidiabetic drugs
Medication utilization was identified using drug_no in 
the NHIRD and linked to the Anatomical Therapeutic 
Chemical (ATC) Classification System used to classify 
active ingredients of antidiabetic drugs: metformin, SU, 
DPP4i, pioglitazone, rosiglitazone, meglitinides, acar-
bose, and insulin. Patients were considered as unexposed 
to antidiabetic drugs (no antidiabetic drug exposure) if 
there was a gap of 30 days or more between two consecu-
tive antidiabetic drug refills (“grace period”).
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Statistics
Population characteristics were analyzed using descrip-
tive statistics, including means, standard deviation, fre-
quency, and proportion. The crude incidence rate of CVD 
was calculated as the total number of CVD events during 
the follow-up period divided by person-years at risk. The 
person-years at risk was defined as the sum of patients 
from the index date (the first antidiabetic drug claim) to 
the diagnosis of the first CVD event, death, or the end of 
2013, whichever came first. The time-varying Cox pro-
portional hazards model was applied to evaluate the time 
to event for the effect of exposure to antidiabetic agents, 
adjusted for patients’ baseline characteristics: age, gen-
der, comorbidity from 1 year prior to the index date (via 
Charlson comorbidity index; CCI [22]), diabetic com-
plications (via adapted Diabetes Complication Severity 
Index; aDCSI [23–25]), CVD history, and co-medications 
for CVD, including α-blockers, β-blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor 
blockers, calcium channel blockers, anti-platelet agents, 
anti-coagulants, diuretics, digoxin, and nitroglycerin.
The aforementioned baseline characteristics were 
treated as fixed effects in the Cox model, while antidia-
betic drug exposure in the follow-up period was the ran-
dom effect. Time-varying exposure to antidiabetic drugs 
was based on the expected duration of each prescription 
by using the “days supplied” field in the NHIRD. We first 
analyzed the outcomes of various antidiabetic drugs (i.e., 
DPP4i vs. non-DPP4i exposure, which included met-
formin, SU, pioglitazone, rosiglitazone, meglitinides, 
acarbose, and insulin, and non-antidiabetic drug expo-
sure). Second, we assessed the comparative outcomes 
of antidiabetic drugs, where DPP4i served as the refer-
ence for comparison with other antidiabetic drugs. We 
attributed outcome events to the drugs the patient was 
expected to be receiving at the time of the event. We 
assumed no legacy or carryover effects of remote expo-
sure to any of the antidiabetic drugs. Subgroup analyses 
were stratified by patients’ CVD history. Hazard ratios 
(HRs) and associated 95  % confidence intervals (CIs) 
adjusted for cluster variance were computed. The sig-
nificance level of this study was set at 0.05. SAS soft-
ware (version 9.4) was utilized for the aforementioned 
analyses.
Results
A total of 123,050 new users of oral antidiabetic drugs 
were included (Fig.  1), where metformin was the most 
commonly prescribed antidiabetic drug, and followed for 
a total of 362,656 person-years.
Table  1 shows the patients’ characteristics according 
to antidiabetic drug exposure at any point during the 
study. We identified 28,508 (8.1 %) patients who received 
DPP4i. Meglitinides users were relatively older and had 
more comorbidities and diabetic complications as com-
pared to those exposed to other antidiabetic drugs.
Table 2 shows CVD risks for each antidiabetic drug as 
compared with non-exposure to a given antidiabetic drug 
(e.g., DPP4i users vs. non-DPP4i users). DPP4i, SU, acar-
bose, metformin, and pioglitazone users had significantly 
lower CVD risks than those of their counterparties (non-
exposure to these drugs), while meglitinides and insulin 
users had significantly higher CVD risks as compared 
with those of patients without exposure to these drugs. 
There was no statistical difference in CVD risks between 
rosiglitazone users and non-rosiglitazone users.
Table 3 shows the comparative CVD and hypoglycemic 
risks of antidiabetic drugs, where DPP4i served as the 
reference. DPP4i users had a significantly lower risk for 
MACEs than that of meglitinides and insulin users, but 
higher than that of metformin and pioglitazone users. 
Also, DPP4i users had a significantly lower stroke risk 
than that of meglitinides and insulin users, but higher 
than that of pioglitazone users. DPP4i users had a signifi-
cantly lower MI risk than that of meglitinides and insu-
lin users, but higher than that of metformin users. DPP4i 
users had a significantly lower HF risk than that of meg-
litinides and insulin users, but higher than that of SU and 
metformin users. DPP4i users had a significantly lower 
hypoglycemic risk than that of meglitinides and insulin 
users, but higher than that of metformin users. Subgroup 
analyses for the patients with and without CVD history 
(Tables  4, 5) show trends similar to those from the pri-
mary analysis (Table 3).
Discussion
This was a large cohort study with a long-term follow-
up to assess CVD and hypoglycemic risks of DPP4i as 
compare with other antidiabetic drugs. DPP4i users had 
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significantly lower CVD risks as compared to non-DPP4i 
users. DPP4i users had significantly lower CVD risks 
than that for those treated with meglitinides and insulin, 
but not than that for those treated with metformin and 
pioglitazone.
Comparison with previous studies
Several studies have evaluated CVD risks in DPP4i users 
as compared to those of non-DPP4i users, which are 
similar to the approach in the first part of our analysis 
(the results presented in Table  2). Eurich et  al.’s study, 
based on commercially insured US claims, showed that 
sitagliptin users did not have increased risks for CVD-
related hospitalizations as compared with those of 
non-sitagliptin users (0.90, 95 % CI 0.77–1.07) [26]. Kim 
et al. utilized US commercial insurance claims data and 
found that DPP4i users had significantly lower risks for 
composite CVD events (including stroke, MI, and HF) 
(0.87, 95  % CI 0.79–0.96), with similar trends observed 
in patients with CVD history [16]. Chen et al.’s study uti-
lized Taiwan’s NHIRD 2009–2011 and found that DPP4i 
use in T2DM patients with stroke [27] or MI [28] his-
tory was not associated with increased CVD risks as 
compared with non-DPP4i users. Consistent with the 
aforementioned studies, the present research based on 
Taiwan’s NHIRD 1999–2013 found that DPP4i users did 
not have increased risks for CVD as compared with non-
DPP4i users (Table 2).
1999-2013 Longitudinal Cohort of Diabetes Patients (LHDB) 
(n = 1,214,213)
From 2009-2010 LHDB (n = 510,478)
Type 2 diabetes mellitus (ICD-9: 250.0X-250.9X, X = 0, 2)
Stable antidiabetic treatment (3 consecutive refills and any 
gaps between two refills of fewer than 30 days)








Use of any antidiabetic drugs prior to the index date, which was the 
claim date of the first antidiabetic drug prescribed in 2009-2011
Fig. 1 Flow diagram of the selection of study population
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Comparative CVD risks of DPP4i with other 
antidiabetic drugs
We further performed comparative analysis of CVD 
risks of antidiabetic drugs. DPP4i users appeared to have 
lower CVD risks as compared with those of insulin and 
meglitinides users, but higher CVD risks than those of 
metformin and pioglitazone users. Eurich et  al.’s study 
found that insulin users had significantly higher risks for 
CVD-related hospitalizations than those of non-insulin 
users (HR 2.15, 95 CI %: 1.85–2.51) [26]. Several possible 
reasons may explain the high CVD risks in insulin users. 
First, a harmful effect of insulin on the vascular endothe-
lium has been suggested and increased insulin dosage 
appeared to be associated with increased CVD risks [29]. 
Second, hypoglycemia is a common side effect observed 
in insulin users. Hypoglycemia has been associated with 
increased CVD risks. The present study found that insu-
lin-treated T2DM patients had 4.55 times higher hypo-
glycemic risk as compared to that of those treated with 
DPP4i (Table 3), which might in part explain higher CVD 
risks in insulin users.
Meglitinides have been related to variable degrees of 
undesirable CVD risks [30]. Repaglinide, a meglitinide 
that acts by closing ATP-dependent potassium channels, 
appears to be associated with a risk of adverse cardiovas-
cular sequelae similar to that for SU [30]. Additionally, 
Table 1 Patients’ characteristics according to antidiabetic drug exposure at any point during the study
DPP4i dipeptidyl peptidase-4 inhibitors, CCI Charlson Comorbidity Index, aDCSI adapted diabetes complication severity index, CAD coronary artery diseases, CCB 



















n 172,813 101,166 6831 1018 22,800 13,103 28,508 9632
Age 57.3 ± 13.2 58.0 ± 13.2 56.3 ± 12.6 55.8 ± 13.5 58.4 ± 13.8 61.6 ± 14.5 56.6 ± 13.2 60.9 ± 15.3
Sex (male), % 51.86 54.20 52.82 59.30 51.98 53.92 54.07 56.34
CCI (1–33) 4.3 ± 3.0 4.2 ± 3.1 4.1 ± 2.9 4.3 ± 3.1 4.7 ± 3.2 5.1 ± 3.4 4.4 ± 3.0 4.9 ± 3.5
aDCSI (0–13) 1.7 ± 2.3 1.8 ± 2.5 1.7 ± 2.4 2.1 ± 2.9 2.2 ± 2.9 2.8 ± 3.5 2.1 ± 2.8 2.6 ± 3.4
Comorbidity history
Hypertension (%) 63.67 63.14 62.88 60.11 65.82 68.67 63.89 66.01
Dyslipidemia (%) 55.70 52.66 56.68 53.13 53.90 58.13 56.94 59.06
CAD (%) 31.68 30.72 30.26 29.16 35.01 38.13 32.07 35.22
Heart failure (%) 8.48 8.89 7.23 7.51 10.54 14.85 9.46 14.70
Stroke (%) 17.74 17.51 14.33 18.34 19.57 25.06 17.38 25.13
Medication history
α‑Blockers (%) 3.49 3.66 3.00 3.22 4.11 5.16 3.68 4.62
β‑Blockers (%) 20.05 19.56 18.83 18.78 20.82 20.22 20.68 18.66
Diuretics (%) 16.57 16.96 15.59 13.15 17.72 19.99 14.67 19.36
CCB (%) 35.64 35.73 36.01 29.52 36.09 37.87 34.01 35.42
AECI/ARB (%) 32.60 31.48 34.48 35.06 36.20 35.29 38.46 32.82
Lipid lowering agent 
(%)
33.93 31.64 38.72 32.65 35.69 29.60 37.11 25.92
Anti‑platelet (%) 24.53 23.84 23.35 23.43 28.05 30.75 26.56 28.98
NTG (%) 4.06 3.86 3.38 4.29 5.17 5.52 5.16 5.30
Anti‑coagulants (%) 0.76 0.87 0.54 0.98 1.06 1.36 1.01 1.56
Digoxin (%) 1.82 2.00 1.52 2.42 2.33 3.59 2.05 3.60
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we found that meglitinides users appeared to be older 
and advanced diabetic patients, in terms of comorbid-
ity and diabetic complications, as compared to those 
treated with other OHAs (i.e., DPP4i) (Table  1). And, 
meglitinides users had a significantly higher CVD risks as 
compared with non-meglitinides users (Table 2). Megli-
tinides users might thus have poor prognosis and higher 
CVD risks as compared to those on other OHAs such as 
DPP4i (Table 3).
Previous evidence showed that metformin users had 
significantly lower CVD risks as compared with non-
metformin users, with a possible mechanism being the 
attenuation of atrial cell tachycardia-induced myolysis 
oxidative stress [31]. Limited research has compared the 
CVD risks of DPP4i users with those of metformin users. 
A recent clinical trial showed that, in terms of glycemic 
control, metformin monotherapy was superior to DPP4i 
monotherapy; however, no difference in CVD risks 
between the two treatment groups were noticed, in part 
due to the limited study period (i.e., 12 months) [32]. This 
observational study with a relatively long follow-up time 
showed that metformin appeared to be associated with 
significantly lower CVD risks as compared to DPP4i.
TZDs (i.e., rosiglitazone,pioglitazone) have been 
associated with increased risks for stroke, HF, and all-
cause mortality [33–36], which appeared to be largest 
in the elderly (i.e., >60  years) and in patients treated 
with rosiglitazone [36]. Practice guidelines state that 
rosiglitazone and pioglitazone are not recommended 
for diabetic patients with pre-existing heart diseases 
or at risk for CVD (i.e., decreased ventricular func-
tion) [37]. Accordingly, the patients who receive TZDs 
are likely to be underlying at low CVD risks. Based on 
our cohort, we found that TZDs users had relatively 
Table 2 Hazard ratios of major adverse cardiovascular events (MACEs) associated with exposure to various antidiabetic 
drugs
HR hazard ratio, CI confidence interval, DPP4i dipeptidyl peptidase-4 inhibitors
* Adjusted hazard ratios were estimated from the Cox models adjusted for age, sex, diabetes duration, comorbidity history (hypertension, hyperlipidemia, coronary 
artery diseases, stroke, myocardial infarction, heart failure, Charlson comorbidity index), diabetic complications (via adapted diabetic complication severity index), 
co-medications (α-blockers, β-blockers, diuretics, calcium channel blockers, angiotensin-II-converting enzyme inhibitors/angiotensin receptor blockers, lipid-lowering 
agents, anti-platelet agents/anticoagulants, nitroglycerin, digoxin)
MACEs Time at risk  
(person-years)




Adjusted HR*  
(95 % CI)
p value
DPP4i 28,508 39.56 0.82 0.83 (0.76, 0.91) <0.0001
(ref.=non‑DPP4i users) 334,148 41.53 – – –
Sulfonylureas 110,618 35.99 0.67 0.80 (0.77, 0.84) <0.0001
(ref. = non‑sulfonylureas users) 252,038 43.74 – – –
Acarbose 22,800 48.37 1.01 0.92 (0.85, 0.99) 0.0463
(ref. = non‑acarbose users) 339,856 26.10 – – –
Meglitinides 13,103 102.49 2.23 1.46 (1.35, 1.58) <0.0001
(ref. = non‑meglitinide users) 349,553 39.08 – – –
Insulin 9632 206.06 4.75 3.53 (3.23, 3.87) <0.0001
(ref. = non‑insulin users) 353,024 36.88 – – –
Metformin 172,813 30.87 0.48 0.66 (0.63, 0.69) <0.0001
(ref. = non‑metformin users) 189,843 45.00 – – –
Pioglitazone 4678 24.15 0.49 0.61 (0.50, 0.75) <0.0001
(ref. = non‑pioglitazone users) 357,978 41.60 – – –
Rosiglitazone 504 35.64 0.69 0.78 (0.49, 1.26) 0.3187
(ref. = non‑rosiglitazone users) 362,152 41.38 – – –
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Table 3 Hazard ratios of  cardiovascular diseases and  hypoglycemic events associated with  various antidiabetic drugs, 
as compared to DPP4i as reference
Time at risk  
(person-years)
Incidence rate  
(per 1000 person-years)
Unadjusted HR  
(95 % CI)






28,508 39.56 – – –
No antidiabetic drug 101,166 62.02 1.52 (1.39, 1.65) 1.31 (1.20, 1.43) <0.0001
Sulfonylureas 110,618 35.99 0.89 (0.81, 0.96) 0.96 (0.88, 1.05) 0.3942
Acarbose 22,800 48.37 1.20 (1.08, 1.33) 1.07 (0.96, 1.18) 0.2098
Meglitinides 13,103 102.49 2.52 (2.27, 2.78) 1.68 (1.52, 1.86) <0.0001
Insulin 9632 206.06 5.08 (4.60, 5.61) 3.73 (3.35, 4.14) <0.0001
Metformin 172,813 30.87 0.76 (0.69, 0.82) 0.87 (0.79, 0.94) 0.0009
Pioglitazone 4678 24.15 0.59 (0.47, 0.73) 0.70 (0.56, 0.86) 0.0011




28,508 20.69 – – –
No antidiabetic drug 101,166 35.83 1.68 (1.49, 1.89) 1.42 (1.26, 1.60) <0.0001
Sulfonylureas 110,618 21.95 1.03 (0.92, 1.16) 1.06 (0.94, 1.19) 0.3465
Acarbose 22,800 26.18 1.24 (1.08, 1.43) 1.09 (0.94, 1.25) 0.2432
Meglitinides 13,103 50.98 2.39 (2.07, 2.75) 1.58 (1.37, 1.81) <0.0001
Insulin 9632 111.07 5.23 (4.58, 5.97) 3.99 (3.47, 4.56) <0.0001
Metformin 172,813 20.61 0.97 (0.86, 1.08) 1.03 (0.92, 1.15) 0.5630
Pioglitazone 4678 13.25 0.62 (0.47, 0.82) 0.71 (0.53, 0.94) 0.0166




28,508 5.19 – – –
No antidiabetic drug 101,166 7.01 1.47 (1.20, 1.80) 1.45 (1.18, 1.78) 0.0003
Sulfonylureas 110,618 4.21 0.83 (0.68, 1.01) 0.98 (0.80, 1.78) 0.8257
Acarbose 22,800 5.08 1.00 (0.77, 1.29) 0.98 (0.75, 1.27) 0.8993
Meglitinides 13,103 9.53 1.89 (1.49, 2.39) 1.49 (1.17, 1.90) 0.0011
Insulin 9632 17.64 3.43 (2.72, 4.33) 2.77 (2.17, 3.51) <0.0001
Metformin 172,813 3.30 0.66 (0.54, 0.79) 0.80 (0.50, 1.39) 0.0234
Pioglitazone 4678 3.63 0.70 (0.42, 1.16) 0.84 (0.50, 1.39) 0.5007




28,508 15.92 – – –
No antidiabetic drug 101,166 25.23 1.50 (1.30, 1.71) 1.28 (1.11, 1.47) 0.0004
Sulfonylureas 110,618 11.78 0.71 (0.62, 0.81) 0.86 (0.74, 1.08) 0.0322
Acarbose 22,800 19.82 1.21 (1.03, 1.42) 1.08 (0.92, 1.26) 0.3227
Meglitinides 13,103 48.23 2.91 (2.48, 3.40) 1.85 (1.58, 2.16) <0.0001
Insulin 9632 92.80 5.67 (4.87, 6.58) 3.71 (3.14, 4.37) <0.0001
Metformin 172,813 8.51 0.51 (0.44, 0.59) 0.66 (0.57, 0.75) <0.0001
Pioglitazone 4678 9.40 0.57 (0.39, 0.80) 0.76 (0.53, 1.07) 0.1229




28,508 5.82 – – –
No antidiabetic drug 101,166 5.23 0.83 (0.67, 1.00) 0.76 (0.62, 0.92) 0.0053
Sulfonylureas 110,618 6.21 1.00 (0.84, 1.19) 1.08 (0.91, 1.29) 0.3621
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lower hypertension, dyslipidemia, coronary artery dis-
eases, HF, and stroke at baseline as compared to those 
of patients exposed to DPP4i (Table  1), which might 
explain lower CVD risks in TZDs-treated patients (e.g., 
pioglitazone) as compared with those of DPP4i users. In 
other words, there appears to be potential confounding 
by indication regarding TZDs use, which might influ-
ence our comparative analysis of CVD risks between 
TZDs and DPP4i. Although we adjusted for patients’ 
baseline comorbidities (i.e., CVD history) in the analy-
sis and stratified the analysis by patients’ CVD history, 
other unmeasured biases (e.g., weight gain, diet, exer-
cise, physicians’ behaviors) for CVD outcomes may 
still exist. We were thus unable to determine whether 
DPP4i use is associated with lower or higher CVD risks 
as compared to TZDs because potential confounding by 
indication could not be excluded.
A recent review of vitro studies and preliminary trials 
concluded potential cardiovascular benefits of alpha-
glucosidase inhibitors (i.e., acarbose) in diabetic patients 
[38], particularly for those with IGT [8, 9]. Interven-
ing on postprandial hyperglycemia, a key component of 
mechanisms linked to increased CVD incidences [39, 
40], acarbose was associated with a favorable impact on 
CVD surrogate markers [41, 42]. Our analysis showed 
that acarbose use was associated with lower CVD risks 
as compared to non-acarbose use (Table  2). However, 
lack of previous research evaluated comparative CVD 
risks between DPP4i and alpha-glucosidase inhibitors. 
Although we found no significant difference in CVD risks 
between DPP4i and acarbose (Table  3), further study is 
needed to confirm our findings, especially for diabetic 
patients with IGT.
Today, most studies compared the CVD risks of DPP4i 
with SU as a group [17, 43, 44], not individual SU. How-
ever, individual SU appear to have different degrees of 
desirable or undesirable cardiovascular effects. Glime-
piride, a  third-generation SU, might provide potential 
cardiovascular benefits because of its favorable glycemic 
control, especially postprandial glucose lowering effects 
[45], anti-oxidative properties [46], and maintaining 
myocardial preconditioning [47]. In terms of reducing 
CVD risks, glimepiride or gliclazide with a specific influ-
ence on pancreatic ATP-sensitive K+ channels might be 
superior to glibenclamide [45], which blocks mitochon-
drial ATP-sensitive K+ channels in cardiac myocytes, 
resulting in the inhibition of ischemic preconditioning 
[48]. Also, a previous population-based cohort study 
The results in italics above indicate significant findings in the Cox models
HR hazard ratio, CI confidence interval, MACEs major adverse cardiovascular events, DPP4i dipeptidyl peptidase-4 inhibitors
* Adjusted hazard ratios were estimated from the Cox models adjusted for age, sex, diabetes duration, comorbidity history (hypertension, hyperlipidemia, coronary 
artery diseases, stroke, myocardial infarction, heart failure, Charlson comorbidity index), diabetic complications (via adapted diabetic complication severity index), 
co-medications (α-blockers, β-blockers, diuretics, calcium channel blockers, angiotensin-II-converting enzyme inhibitors/angiotensin receptor blockers, lipid-lowering 
agents, anti-platelet agents/anticoagulants, nitroglycerin, digoxin)
Table 3 continued
Time at risk  
(person-years)
Incidence rate  
(per 1000 person-years)
Unadjusted HR  
(95 % CI)
Adjusted HR*  
(95 % CI)
p value
Acarbose 22,800 5.83 0.96 (0.77, 1.19) 0.90 (0.72, 1.11) 0.3402
Meglitinides 13,103 18.16 2.91 (2.35, 3.59) 2.09 (1.68, 2.58) <0.0001
Insulin 9632 39.44 6.41 (5.24, 7.84) 4.55 (3.67, 5.64) <0.0001
Metformin 172,813 2.69 0.43 (0.35, 0.52) 0.50 (0.41, 0.60) <0.0001
Pioglitazone 4678 5.77 0.93 (0.62, 1.40) 1.07 (0.71, 1.60) 0.7471
Rosiglitazone 504 11.88 1.50 (0.66, 3.37) 1.58 (0.70, 3.55) 0.2679
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Table 4 Subgroup analysis of hazard ratios of cardiovascular diseases and hypoglycemic events associated with various 
antidiabetic drugs, as compared to DPP4i as reference, in the patients with CVD history
Time at risk  
(person-years)
Incidence rate  
(per 1000 person-years)





Antidiabetic drug (ref. = DPP4i) 11,532 71.79 – –
No antidiabetic drug 43,967 109.05 1.47 (1.32, 1.62) 1.27 (1.14, 1.40)
Sulfonylureas 40,852 67.48 0.92 (0.82, 1.01) 0.97 (0.87, 1.08)
Acarbose 9972 80.52 1.10 (0.97, 1.24) 1.01 (0.89, 1.14)
Meglitinides 6346 160.39 2.16 (1.91, 2.44) 1.54 (1.36, 1.73)
Insulin 3919 362.57 4.90 (0.68, 0.84) 3.30 (2.90, 3.75)
Metformin 67,237 56.33 0.76 (0.51, 0.83) 0.88 (0.78, 0.97)
Pioglitazone 1683 48.72 0.65 (0.51, 0.83) 0.74 (0.57, 0.95)
Rosiglitazone 186 75.00 0.91 (0.53, 1.54) 0.96 (0.56, 1.64)
Ischemic stroke
Antidiabetic drug (ref. = DPP4i) 11,532 37.02 – –
No antidiabetic drug 43,967 61.47 1.61 (1.39, 1.85) 1.38 (1.19, 1.59)
Sulfonylureas 40,852 40.19 1.06 (0.91, 1.22) 1.07 (0.92, 1.23)
Acarbose 9972 41.51 1.10 (0.92, 1.29) 1.01 (0.85,1.18)
Meglitinides 6346 79.40 2.08 (1.75, 2.45) 1.48 (1.24, 1.74)
Insulin 3919 183.96 4.82 (4.10, 5.65) 3.37 (2.86, 3.96)
Metformin 67,237 36.78 0.97 (0.84, 1.10) 1.05 (0.91, 1.20)
Pioglitazone 1683 23.17 0.60 (0.43, 0.84) 0.67 (0.47, 0.94)
Rosiglitazone 186 42.85 1.01 (0.50, 2.02) 0.99 (0.49, 2.00)
Myocardial infarction
Antidiabetic drug (ref. = DPP4i) 11,532 8.67 – –
No antidiabetic drug 43,967 11.05 1.38 (1.08, 1.76) 1.34 (1.04, 1.71)
Sulfonylureas 40,852 7.31 0.87 (0.68, 1.10) 0.99 (0.72, 1.26)
Acarbose 9972 7.82 0.92 (0.67, 1.26) 0.91 (0.66, 1.25)
Meglitinides 6346 13.86 1.65 (1.23, 2.20) 1.32 (0.98, 1.77)
Insulin 3919 27.81 3.25 (2.45, 4.30) 2.41 (1.80, 3.21)
Metformin 67,237 5.35 0.64 (0.50, 0.80) 0.78 (0.61, 0.98)
Pioglitazone 1683 7.12 0.83 (0.45, 1.52) 0.93 (0.50, 1.71)
Rosiglitazone 186 10.71 1.32 (0.33, 5.32) 1.46 (0.36, 5.81)
Heart failure
Antidiabetic drug (ref. = DPP4i) 11,532 30.26 – –
No antidiabetic drug 43,967 48.71 1.52 (1.29, 1.78) 1.28 (1.08, 1.49)
Sulfonylureas 40,852 24.03 0.77 (0.65, 0.90) 0.86 (0.72, 1.02)
Acarbose 9972 36.19 1.17 (0.97, 1.39) 1.07 (0.89, 1.28)
Meglitinides 6346 77.36 2.45 (2.03, 2.95) 1.66 (1.38, 1.98)
Insulin 3919 178.60 5.72 (4.78, 6.83) 3.52 (2.88, 4.28)
Metformin 67,237 17.20 0.55 (0.46, 0.64) 0.68 (0.57, 0.80)
Pioglitazone 1683 23.17 0.73 (0.50, 1.07) 0.89 (0.59, 1.31)
Rosiglitazone 186 21.42 0.61 (0.22, 1.63) 0.72 (0.26, 1.97)
Hypoglycemia
Antidiabetic drug (ref. = DPP4i) 11,532 7.37 – –
No antidiabetic drug 43,967 7.32 0.92 (0.70, 1.20) 0.83 (0.63, 1.07)
Sulfonylureas 40,852 10.13 1.31 (1.02, 1.67) 1.44 (1.12, 1.82)
Acarbose 9972 7.52 0.98 (0.72, 1.32) 0.92 (0.68, 1.24)
Meglitinides 6346 24.10 3.09 (2.35, 4.03) 2.20 (1.68, 2.88)
Insulin 3919 45.67 5.91 (4.50, 7.74) 3.73 (2.77, 5.01)
Metformin 67,237 3.56 0.46 (0.35, 0.59) 0.54 (0.42, 0.70)
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showed that glipizide was associated with increased CVD 
risks as compared to other SU. Hence, further study is 
anticipated to assess whether pharmacological differ-
ences between individual drugs translate into differences 
in their associated CVD risks. Our additional analyses 
showed that, as compared to glibenclamide, gliclazide 
had a significantly lower risk for MACEs, and gliclazide 
and glimepiride had a significantly lower risk for stroke 
(Additional file  1: Table S1). In this regard, we further 
compared the CVD risks of DPP4i with individual SU. 
The results showed that, as compared to DPP4i, glip-
izide and glibenclamide had significantly higher risks for 
MACEs and stroke (Additional file 1: Table S2).
Study limitations
First, laboratory data (e.g., HbA1c) were not available 
in the NHIRD claims data. However, we used surro-
gat indicators to adjust for patients’ baseline diabetes 
severity, including aDCSI and diabetes duration. Sec-
ond, because of the nature of an observational study, 
potential confounding by indication could not be elimi-
nated. Also, potential residual confounding by incom-
plete adjustment for unmeasured biases (i.e., lifestyle 
risk factors, physicians’ preferences and behaviors) 
for study outcomes may exist. Third, another class of 
incretin drug, namely GLP-1 receptor agonists (GLP-1 
RA), was not analyzed. GLP-1 RA was introduced to 
Taiwan’s national formulary in 2013. Since our data 
were only available up to the end of 2013, GLP-1 RA 
users only accounted for a small proportion of our 
study population. Fourth, potential misclassification 
may exist when defining CVD events based on Tai-
wan’s NHIRD. However, previous validation stud-
ies for the identification of CVD events (i.e., MI [49], 
stroke [50]) from the NHIRD showed high sensitivity 
and positive predictive values. Fifth, individual DPP4i 
might be associated with variable degrees of desir-
able or undesirable cardiovascular outcomes [51]. The 
SAVOR-TIMI 53 trial reported an increased HF risk in 
saxagliptin-treated patients [12], which was not seen 
with other DPP4i. The present study analyzed individ-
ual DPP4i as a group because our preliminary analyses 
showed no significant difference in comparative risks 
for MACEs and HF of individual DPP4i (sitagliptin, 
vildagliptin, saxagliptin, linagliptin) (Additional file  1: 
Table S3). Further study is anticipated to clarify the 
mechanisms underlying the difference in CVD risks 
among individual DPP4i. Lastly, our results might only 
be generalizable to a Chinese population under univer-
sal healthcare insurance coverage.
CVD cardiovascular disease, HR hazard ratio, CI confidence interval, MACEs major adverse cardiovascular events, DPP-4 inhibitors dipeptidyl peptidase-4 inhibitors
* Adjusted hazard ratios were estimated from the Cox models adjusted for age, sex, diabetes duration, comorbidity history (hypertension, hyperlipidemia, coronary 
artery diseases, stroke, myocardial infarction, heart failure, Charlson comorbidity index), diabetic complications (via adapted diabetic complication severity index), 
co-medications (α-blockers, β-blockers, diuretics, calcium channel blockers, angiotensin-II-converting enzyme inhibitors/angiotensin receptor blockers, lipid-lowering 
agents, anti-platelet agents/anticoagulants, nitroglycerin, digoxin)
Table 4 continued
Time at risk  
(person-years)
Incidence rate  
(per 1000 person-years)




Pioglitazone 1683 8.31 1.08 (0.61, 1.90) 1.25 (0.70, 2.20)
Rosiglitazone 186 21.42 2.31 (0.84, 6.32) 2.42 (0.88, 6.65)
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Table 5 Subgroup analysis of hazard ratios of cardiovascular diseases and hypoglycemic events associated with various 
antidiabetic drugs, as compared to DPP4i as reference, in the patients without CVD history
Time at risk  
(person-years)
Incidence rate  
(per 1000 person-years)





Antidiabetic drug (ref. = DPP4i) 16,975 17.67 – –
No antidiabetic drug 57,199 25.84 1.50 (1.29, 1.74) 1.38 (1.19, 1.60)
Sulfonylureas 69,766 17.55 0.99 (0.86, 1.15) 0.93 (0.80, 1.07)
Acarbose 12,828 23.38 1.33 (1.10, 1.60) 1.22 (1.01, 1.47)
Meglitinides 6756 48.10 2.73 (2.28, 3.26) 2.04(1.70, 2.44)
Insulin 5713 98.70 5.56 (4.70, 6.58) 5.48 (4.60, 6.50)
Metformin 105,576 14.65 0.83 (0.72, 0.96) 0.82 (0.70, 0.94)
Pioglitazone 2995 10.35 0.58 (0.39, 0.87) 0.61 (0.40, 0.90)
Rosiglitazone 318 12.56 0.68 (0.25, 1.83) 0.68 (0.25, 1.84)
Ischemic stroke
Antidiabetic drug (ref. = DPP4i) 16,975 9.60 – –
No antidiabetic drug 57,199 16.11 1.70 (1.38, 2.07) 1.52 (1.23, 1.86)
Sulfonylureas 69,766 11.28 1.17 (0.96, 1.42) 1.04 (0.85, 1.27)
Acarbose 12,828 14.26 1.49 (1.15, 1.92) 1.34 (1.03, 1.74)
Meglitinides 6756 24.27 2.52 (1.96, 3.22) 1.85 (1.44, 2.36)
Insulin 5713 61.08 6.32 (5.02, 7.94) 6.56 (5.21, 8.27)
Metformin 105,576 10.32 1.07 (0.88, 1.29) 1.01 (0.82, 1.22)
Pioglitazone 2995 7.67 0.80 (0.49, 1.29) 0.81 (0.50, 1.32)
Rosiglitazone 318 12.56 1.21 (0.44, 3.27) 1.22 (0.44, 3.32)
Myocardial infarction
Antidiabetic drug (ref. = DPP4i) 16,975 2.82 – –
No antidiabetic drug 57,199 3.91 1.55 (1.09, 2.20) 1.56 (1.09, 2.22)
Sulfonylureas 69,766 2.39 0.88 (0.63, 1.22) 0.93 (0.66, 1.29)
Acarbose 12,828 2.96 1.08 (0.68, 1.70) 1.09 (0.69, 1.71)
Meglitinides 6756 5.47 2.02 (1.33, 3.04) 1.78 (1.17, 2.69)
Insulin 5713 10.67 3.84 (2.54, 5.79) 3.38 (2.23, 5.10)
Metformin 105,576 1.99 0.74 (0.53, 1.02) 0.81 (0.58, 1.13)
Pioglitazone 2995 1.66 0.59 (0.23, 1.49) 0.63 (0.24, 1.60)
Rosiglitazone 318 0 0 0
Heart failure
Antidiabetic drug (ref. = DPP4i) 16,975 6.18 – –
No antidiabetic drug 57,199 7.18 1.19 (0.92, 1.52) 1.13 (0.87, 1.45)
Sulfonylureas 69,766 4.61 0.75 (0.58, 0.95) 0.73 (0.57, 0.94)
Acarbose 12,828 7.09 1.15 (0.84, 1.56) 1.06 (0.78, 1.44)
Meglitinides 6756 20.86 3.38 (2.55, 4.46) 2.45 (1.85, 3.22)
Insulin 5713 33.95 5.45 (4.17, 7.10) 4.75(3.54, 6.35)
Metformin 105,576 2.97 0.48 (0.37, 0.61) 0.51 (0.39, 0.65)
Pioglitazone 2995 1.66 0.27 (0.10, 0.66) 0.29 (0.11, 0.71)
Rosiglitazone 318 0 0 0
Hypoglycemia
Antidiabetic drug (ref. = DPP4i) 16,975 4.77 – –
No antidiabetic drug 57,199 3.63 0.69 (0.51, 0.92) 0.69 (0.51, 0.92)
Sulfonylureas 69,766 3.92 0.76 (0.59, 0.98) 0.78 (0.60, 1.00)
Acarbose 12,828 4.52 0.91 (0.65, 1.24) 0.89 (0.64, 1.22)
Meglitinides 6756 12.58 2.44 (1.70, 3.49) 1.93 (1.33, 2.77)
Insulin 5713 35.17 6.95 (5.17, 9.34) 5.47 (4.00, 7.48)
Metformin 105,576 2.13 0.41 (0.30, 0.55) 0.46 (0.34, 0.61)
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Conclusions
Understanding comparative effects of antidiabetic drugs 
provides a basis for guiding clinical care for T2DM patients. 
The present study shows that the use of DPP4i was not 
associated with increased CVD risks and that DPP4i-
treated patients appeared to have lower CVD risks as com-
pared with non-DPP4i users, except metformin users.
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